Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.
The antimicrobial susceptibility profile of 419 clinical isolates of Pseudomonas aeruginosa obtained from intensive care unit patients was determined. Amikacin and piperacillin/tazobactam were the most active antimicrobials evaluated. Fifty isolates (11.9%) were resistant to antimicrobials from > or =3 classes. Ninety-six percent of multidrug-resistant (MDR) isolates remained fully susceptible to colistin (polymyxin E).
Walkty
Andrew
A
Department of Medicine, Health Sciences Centre, Winnipeg, MB, Canada. awalkty@mts.net
Decorby
Melanie
M
Nichol
Kim
K
Mulvey
Michael R
MR
Hoban
Daryl
D
Zhanel
George
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002170:Canada; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents